Latest Horizon Pharma Inc (HZNP) Headlines
Will Horizon Pharma Spike Again On Quarterly Report?
at Investor's Business Daily - Wed Mar 12, 7:02AM CDT
Shares of small specialty drug company Horizon Pharma (HZNP) have been on the move since it reported third-quarter results in early November, thanks to expectations for the firm's novel drugs that treat arthritis, pain and inflammatory conditions....
Egalet Appoints Timothy P. Walbert to Board of Directors
GlobeNewswire - Tue Mar 11, 7:14AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced the appointment of Timothy P. Walbert, chairman, president and chief executive officer of Horizon Pharma, to its board of directors.
Horizon Pharma announces grant of stock option to two new employees under NASDAQ Listing Rule 5635(c)(4)
M2 - Fri Mar 07, 6:27AM CST
Pharmaceutical company Horizon Pharma (NASDAQ:HZNP) said on Thursday that it has announced inducement awards to two new employees entering into employment with the company.
Horizon Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Marketwire - Thu Mar 06, 6:30AM CST
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that the Compensation Committee of its Board of Directors granted inducement awards to two new employees.
Horizon Pharma to Present at the 26th Annual ROTH Conference
Marketwire - Thu Mar 06, 6:30AM CST
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Todd Smith, executive vice president and chief commercial officer, will present at the 26th Annual ROTH Conference on Monday, March 10th at 9:00 a.m. Pacific Time in Laguna Nigel, CA. Mr. Smith will provide an overview of the Company and its corporate activities.
Financial Results Releases and Schedules, Clinical Study Results, Partnerships, and Senior-Level Appointments - Analyst Notes on Arena, Horizon Pharma, Enanta, Vanda, and PTC
PR Newswire - Wed Mar 05, 2:30PM CST
Editor Note: For more information about this release, please scroll to bottom.
Horizon Pharma Names Robert F. Carey Executive Vice President and Chief Business Officer
Marketwire - Wed Mar 05, 6:30AM CST
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced the appointment of Robert F. Carey as executive vice president and chief business officer, bringing a broad base of healthcare investment banking experience. Mr. Carey has assisted biotech and specialty pharma companies raise more than $10 billion in initial public offerings, follow-on offerings, debt offerings and private placements. He has also served as a financial advisor on mergers, acquisitions and strategic alliance transactions with a total deal value of more than $3 billion.
Zacks Investment Ideas feature highlights: Emergent Biosolutions, Horizon Pharma and Medivation
PR Newswire - Fri Feb 28, 8:30AM CST
Today, Zacks Investment Ideas feature highlights Features: Emergent Biosolutions (NYSE:EBS-Free Report), Horizon Pharma Inc (Nasdaq:HZNP-Free Report) and Medivation (Nasdaq:MDVN-Free Report).
Ask a Fool: What Is Your Foolish Opinion of Horizon Pharma?
Max Macaluso, The Motley Fool - Motley Fool - Thu Feb 27, 4:31PM CST
In this video from The Motley Fool's "Ask a Fool" series, Fool health-care analyst Max Macaluso takes a question from a Fool reader, who asks, "What is your Foolish opinion of Horizon Pharma ?" This commercial-stage biotech company has seen its...
Biopharms That Won't Buy The Farm - Investment Ideas
David Bartosiak - Zacks Investment Research - Thu Feb 27, 2:37PM CST
Biopharms That Won't Buy The Farm - Investment Ideas
Horizon Pharma to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2013 Financial Results on March 13, 2014
Marketwire - Thu Feb 27, 6:44AM CST
Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that its fourth quarter and year ended December 31, 2013 financial results will be released on Thursday, March 13, 2014. Following the announcement, Horizon's management will host a live conference call and webcast at 8:00 am Eastern Time to review the Company's financial and operating results and provide a general business update.
Can Horizon Pharma (HZNP) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 7:36AM CST
Horizon Pharma could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision front
Should You Worry About the Short Interest in Horizon Pharma (HZNP)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 9:13AM CST
Should You Worry About the Short Interest in Horizon Pharma (HZNP)?
Horizon Pharma to Present at the Cowen and Company 34th Annual Health Care Conference
Marketwire - Mon Feb 24, 6:30AM CST
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Timothy P. Walbert, chairman, president and chief executive officer, will present at the Cowen and Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 2:10 p.m. Eastern Time in Boston, MA. Mr. Walbert will provide an overview of the Company and its corporate activities.
Pozen's Wagon is Tied to Horizon and Sanofi
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 21, 1:30PM CST
Sometimes collaboration deals with big pharmaceutical companies don't work out, and that was the case with Pozen's once-lucrative partnership with AstraZeneca The two teamed up to develop arthritis drug Vimovo in 2006, but sales have been elusive...
Horizon Pharma (HZNP) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 8:14AM CST
Horizon Pharma (HZNP) Shares March Higher, Can It Continue?
Horizon Pharma Provides Update on February 10-11, 2014 FDA Joint Advisory Committee Meeting on Cardiovascular Risk of NSAIDs
Marketwire - Tue Feb 11, 3:40PM CST
Horizon Pharma, Inc., (NASDAQ: HZNP), a commercial stage, specialty pharmaceutical company that markets two gastroprotective nonsteroidal anti-inflammatory drugs (NSAIDs), VIMOVO(R) (naproxen/esomeprazole magnesium) and DUEXIS(R) (ibuprofen and famotidine), announced that the FDA joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee was split on whether the data show adequate differences in cardiovascular risk among NSAIDs to support labeling change for NSAIDs due to cardiovascular (CV) risk. The committee found that there was not enough data at this time to differentiate among the NSAIDs. During the discussion, the committee did recognize the risk of gastrointestinal (GI) events when taking NSAIDs. The FDA will take the committee's discussion into consideration and will make the final determination in this matter.
Horizon Pharma Inc reports inducement grants to new employees under NASDAQ Listing Rule 5635(c)(4)
M2 - Fri Feb 07, 6:59AM CST
Specialty pharmaceutical company Horizon Pharma Inc (NASDAQ:HZNP) on Thursday announced the grant of inducement stock options to purchase an aggregate of 78,750 shares of its common stock.
Will Horizon Pharma Spike Again On Quarterly Report?
at Investor's Business Daily - Wed Mar 12, 7:02AM CDT
Shares of small specialty drug company Horizon Pharma (HZNP) have been on the move since it reported third-quarter results in early November, thanks to expectations for the firm's novel drugs that treat arthritis, pain and inflammatory conditions....
Egalet Appoints Timothy P. Walbert to Board of Directors
GlobeNewswire - Tue Mar 11, 7:14AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced the appointment of Timothy P. Walbert, chairman, president and chief executive officer of Horizon Pharma, to its board of directors.
Horizon Pharma announces grant of stock option to two new employees under NASDAQ Listing Rule 5635(c)(4)
M2 - Fri Mar 07, 6:27AM CST
Pharmaceutical company Horizon Pharma (NASDAQ:HZNP) said on Thursday that it has announced inducement awards to two new employees entering into employment with the company.
Horizon Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Marketwire - Thu Mar 06, 6:30AM CST
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that the Compensation Committee of its Board of Directors granted inducement awards to two new employees.
Horizon Pharma to Present at the 26th Annual ROTH Conference
Marketwire - Thu Mar 06, 6:30AM CST
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Todd Smith, executive vice president and chief commercial officer, will present at the 26th Annual ROTH Conference on Monday, March 10th at 9:00 a.m. Pacific Time in Laguna Nigel, CA. Mr. Smith will provide an overview of the Company and its corporate activities.
Financial Results Releases and Schedules, Clinical Study Results, Partnerships, and Senior-Level Appointments - Analyst Notes on Arena, Horizon Pharma, Enanta, Vanda, and PTC
PR Newswire - Wed Mar 05, 2:30PM CST
Editor Note: For more information about this release, please scroll to bottom.
Horizon Pharma Names Robert F. Carey Executive Vice President and Chief Business Officer
Marketwire - Wed Mar 05, 6:30AM CST
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced the appointment of Robert F. Carey as executive vice president and chief business officer, bringing a broad base of healthcare investment banking experience. Mr. Carey has assisted biotech and specialty pharma companies raise more than $10 billion in initial public offerings, follow-on offerings, debt offerings and private placements. He has also served as a financial advisor on mergers, acquisitions and strategic alliance transactions with a total deal value of more than $3 billion.
Zacks Investment Ideas feature highlights: Emergent Biosolutions, Horizon Pharma and Medivation
PR Newswire - Fri Feb 28, 8:30AM CST
Today, Zacks Investment Ideas feature highlights Features: Emergent Biosolutions (NYSE:EBS-Free Report), Horizon Pharma Inc (Nasdaq:HZNP-Free Report) and Medivation (Nasdaq:MDVN-Free Report).
Ask a Fool: What Is Your Foolish Opinion of Horizon Pharma?
Max Macaluso, The Motley Fool - Motley Fool - Thu Feb 27, 4:31PM CST
In this video from The Motley Fool's "Ask a Fool" series, Fool health-care analyst Max Macaluso takes a question from a Fool reader, who asks, "What is your Foolish opinion of Horizon Pharma ?" This commercial-stage biotech company has seen its...
Biopharms That Won't Buy The Farm - Investment Ideas
David Bartosiak - Zacks Investment Research - Thu Feb 27, 2:37PM CST
Biopharms That Won't Buy The Farm - Investment Ideas
Horizon Pharma to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2013 Financial Results on March 13, 2014
Marketwire - Thu Feb 27, 6:44AM CST
Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that its fourth quarter and year ended December 31, 2013 financial results will be released on Thursday, March 13, 2014. Following the announcement, Horizon's management will host a live conference call and webcast at 8:00 am Eastern Time to review the Company's financial and operating results and provide a general business update.
Can Horizon Pharma (HZNP) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 7:36AM CST
Horizon Pharma could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision front
Should You Worry About the Short Interest in Horizon Pharma (HZNP)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 9:13AM CST
Should You Worry About the Short Interest in Horizon Pharma (HZNP)?
Horizon Pharma to Present at the Cowen and Company 34th Annual Health Care Conference
Marketwire - Mon Feb 24, 6:30AM CST
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Timothy P. Walbert, chairman, president and chief executive officer, will present at the Cowen and Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 2:10 p.m. Eastern Time in Boston, MA. Mr. Walbert will provide an overview of the Company and its corporate activities.
Pozen's Wagon is Tied to Horizon and Sanofi
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 21, 1:30PM CST
Sometimes collaboration deals with big pharmaceutical companies don't work out, and that was the case with Pozen's once-lucrative partnership with AstraZeneca The two teamed up to develop arthritis drug Vimovo in 2006, but sales have been elusive...
Horizon Pharma (HZNP) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 8:14AM CST
Horizon Pharma (HZNP) Shares March Higher, Can It Continue?
Horizon Pharma Provides Update on February 10-11, 2014 FDA Joint Advisory Committee Meeting on Cardiovascular Risk of NSAIDs
Marketwire - Tue Feb 11, 3:40PM CST
Horizon Pharma, Inc., (NASDAQ: HZNP), a commercial stage, specialty pharmaceutical company that markets two gastroprotective nonsteroidal anti-inflammatory drugs (NSAIDs), VIMOVO(R) (naproxen/esomeprazole magnesium) and DUEXIS(R) (ibuprofen and famotidine), announced that the FDA joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee was split on whether the data show adequate differences in cardiovascular risk among NSAIDs to support labeling change for NSAIDs due to cardiovascular (CV) risk. The committee found that there was not enough data at this time to differentiate among the NSAIDs. During the discussion, the committee did recognize the risk of gastrointestinal (GI) events when taking NSAIDs. The FDA will take the committee's discussion into consideration and will make the final determination in this matter.
Horizon Pharma Inc reports inducement grants to new employees under NASDAQ Listing Rule 5635(c)(4)
M2 - Fri Feb 07, 6:59AM CST
Specialty pharmaceutical company Horizon Pharma Inc (NASDAQ:HZNP) on Thursday announced the grant of inducement stock options to purchase an aggregate of 78,750 shares of its common stock.
